• MeSH
• dítě MeSH
• jednotky intenzivní péče MeSH
• kojenec MeSH
• lidé MeSH
• mladiství MeSH
• nedepolarizující myorelaxancia farmakologie   MeSH
• nervosvalová blokáda metody   MeSH
• nervosvalové spojení účinky léků   MeSH
• opožděné probouzení z anestezie diagnóza   MeSH
• peroperační monitorování metody   MeSH
• předškolní dítě MeSH
• Check Tag
• dítě MeSH
• kojenec MeSH
• lidé MeSH
• mladiství MeSH
• předškolní dítě MeSH
• Publikační typ
• dopisy MeSH
• pozorovací studie MeSH

BACKGROUND: Proper management of multiple sclerosis (MS) requires feedback from clinical practice via registries. OBJECTIVE: To introduce the Czech national multiple sclerosis registry, ReMuS, and explore the availability and use of disease-modifying drugs (DMD). METHODS: The analysis focused on patients who started their first DMD, either with first-line or second-line medication and was based on reimbursement criteria set by Czech regulators. Baseline information was used to predict relapses after DMD initiation and to compare patients that started DMD in different years. RESULTS: A total of 3,328 patients started DMD treatment for MS between 2013 and 2016; 3,203 on first-line and 125 on second-line medication. The proportion of patients starting on second-line drugs increased from 1.8% in 2013 to 4.7% in 2016. The occurrence of a relapse within one year of DMD initiation was significantly related to (1) the Expanded Disability Status Scale (EDSS) score immediately prior to starting DMD and (2) the number of previous relapses. Both parameters were significantly lower in patients starting in later years of the explored interval. CONCLUSION: Data from the ReMuS registry highlights improvements made in the management of MS in the Czech Republic. However, a relatively low percentage of patients started treatment using second-line drugs, in contrast to trends in other countries.

• MeSH
• dospělí MeSH
• imunologické faktory terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• progrese nemoci MeSH
• recidiva MeSH
• registrace MeSH
• roztroušená skleróza farmakoterapie   MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Česká republika MeSH

• MeSH
• anesteziologie MeSH
• kongresy jako téma MeSH
• resuscitace MeSH
• Publikační typ
• zprávy MeSH

BACKGROUND AND PURPOSE: The aim was to report the clinical characteristics of 12 patients with limbic encephalitis (LE) who were antibody-negative after a comprehensive immunological study. METHODS: The clinical records of 163 patients with LE were reviewed. Immunohistochemistry on rat brain, cultured neurons and cell-based assays were used to identify neuronal autoantibodies. Patients were included if (i) there was adequate clinical, cerebrospinal fluid (CSF) and magnetic resonance imaging information to classify the syndrome as LE, (ii) magnetic resonance images were accessible for central review and (iii) serum and CSF were available and were confirmed negative for neuronal antibodies. RESULTS: Twelve (7%) of 163 LE patients [median age 62 years; range 40-79; 9 (75%) male] without neuronal autoantibodies were identified. The most frequent initial complaints were deficits in short-term memory leading to hospital admission in a few weeks (median time 2 weeks; range 0.5-12). In four patients the short-term memory dysfunction remained as an isolated symptom during the entire course of the disease. Seizures, drowsiness and psychiatric problems were unusual. Four patients had solid tumors (one lung, one esophagus, two metastatic cervical adenopathies of unknown primary tumor) and one chronic lymphocytic leukemia. CSF showed pleocytosis in seven (58%) with a median of 13 white blood cells/mm3 (range 9-25). Immunotherapy included corticosteroids, intravenous immunoglobulins and combinations of both drugs or with rituximab. Clinical improvement occurred in six (54%) of 11 assessable patients. CONCLUSIONS: Despite the discovery of new antibodies, 7% of LE patients remain seronegative. Antibody-negative LE is more frequent in older males and usually develops with predominant or isolated short-term memory loss. Despite the absence of antibodies, patients may have an underlying cancer and respond to immunotherapy.

• MeSH
• autoantigeny imunologie   MeSH
• autoprotilátky analýza   MeSH
• dospělí MeSH
• imunohistochemie MeSH
• imunoterapie MeSH
• krátkodobá paměť MeSH
• krysa rodu rattus MeSH
• kultivované buňky MeSH
• leukocytóza MeSH
• leukocyty imunologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• limbická encefalitida imunologie   psychologie   terapie   MeSH
• magnetická rezonanční tomografie MeSH
• nádory komplikace   MeSH
• neurony imunologie   MeSH
• poruchy paměti etiologie   psychologie   MeSH
• senioři MeSH
• výsledek terapie MeSH
• zvířata MeSH
• Check Tag
• dospělí MeSH
• krysa rodu rattus MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Research Support, N.I.H., Extramural MeSH

BACKGROUND: The purpose of this international survey was to describe the current practices and techniques of labor analgesia in the Czech Republic (CZE) and Slovakia (SVK). METHODS: All Czech and Slovak departments that provide obstetric anesthesia were invited to participate in a one-month (November 2015) prospective study that monitored in detail all peripartum anesthetic procedures delivered by anesthesiologists. Participating centers recorded all data on-line in the CLADE-IS database (Masaryk University, CZE). RESULTS: The response rate was 71% (70 of 95 departments in CZE, 35 of 54 centers in SVK). Participating centers represented 87.7% of all births in CZE and 66.4% of all births in SVK during the study period. Analgesia for labor, administered by anesthesiologists, was recorded in 12.5% of deliveries (CZE 12.1%, SVK 13.4%). Epidural analgesia was used in most of the cases (CZE 97.2%, SVK 99.1%) whereas spinal (CZE 1.4%, SVK 0.9%) or combined spinal-epidural (CZE 0.5%, SVK 0.0%) and intravenous remifentanil analgesia (CZE 2.4%, SVK 0.0%) were used infrequently. One fifth of the labors with analgesia administered by anesthesiologists (CZE 20.2%, SVK 20.5%) terminated in cesarean section. CONCLUSIONS: Although labor analgesia was available in all Czech and Slovak obstetric centers, only a small proportion of parturients received an effective method of labor pain relief (regional or intravenous analgesia).

• MeSH
• epidurální analgezie škodlivé účinky   metody   MeSH
• lidé MeSH
• porodnická analgezie škodlivé účinky   metody   MeSH
• prospektivní studie MeSH
• průzkumy a dotazníky MeSH
• těhotenství MeSH
• Check Tag
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Slovenská republika MeSH

• MeSH
• androstanoly * MeSH
• celková anestezie MeSH
• císařský řez * MeSH
• lidé MeSH
• porodnická anestezie MeSH
• těhotenství MeSH
• Check Tag
• lidé MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• dopisy MeSH
• komentáře MeSH

BACKGROUND: In a previous study we compared rocuronium and suxamethonium for rapid-sequence induction of general anaesthesia for caesarean section and found no difference in maternal outcome. There was however, a significant difference in Apgar scores. As this was a secondary outcome, we extended the study to explore this finding on a larger sample. METHODS: We included 488 parturients of whom 240 were women from the original study. Women were randomly assigned to receive either rocuronium 1mg/kg (ROC n=245) or suxamethonium 1mg/kg (SUX n=243) after propofol 2mg/kg. Anaesthesia was maintained with up to 50% nitrous oxide and up to one minimum alveolar concentration of sevoflurane until the umbilical cord was clamped. We compared neonatal outcome using Apgar scores and umbilical cord blood gases. RESULTS: Data were analysed for 525 newborns (ROC n=263vs. SUX n=262). There was a statistically significant difference in the proportion of Apgar scores <7 at 1min (ROC 17.5% vs. SUX 10.3%, P=0.023) but no difference at 5min (ROC 8% vs. SUX 4.2%, P=0.1) or 10min (ROC 3.0% vs. SUX 1.9%, P=0.58). There was no difference between groups in other measured outcomes. CONCLUSION: The use of rocuronium was associated with lower Apgar scores at 1min compared with suxamethonium. The clinical significance of this is unclear and warrants further investigation.

• MeSH
• androstanoly farmakologie   MeSH
• Apgar skóre * MeSH
• celková anestezie metody   MeSH
• císařský řez MeSH
• dospělí MeSH
• lidé MeSH
• novorozenec MeSH
• porodnická anestezie metody   MeSH
• sukcinylcholin farmakologie   MeSH
• těhotenství MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• novorozenec MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH

PURPOSE: Aim of this prospective observational study was to analyze fertility status of Hodgkin lymphoma (HL) patients treated with different types of chemotherapy while receiving GnRH analogues to preserve ovarian function. METHODS: Fertility status was assessed among 108 females in reproductive age treated by curative chemotherapy for freshly diagnosed HL between 2005 and 2010 in university-based tertiary fertility and oncology center. All patients received GnRH analogues during chemotherapy to preserve their ovarian function. Their reproductive functions were assessed by follicle-stimulating hormone (FSH) measurement and pregnancy achievement. Ovarian function was determined separately in three groups with increasing gonadotoxicity of chemotherapy. RESULTS: One year following the treatment, normal ovarian function was found in 89 (82.4%) of patients. Two years after chemotherapy, 98 (90.7%) of patients retained their ovarian function, and 23 (21.3%) achieved clinical pregnancy during the follow-up period. Average FSH after chemotherapy was 11.6 ± 17.9 IU/l 1 year after the treatment resp. 9.0 ± 13.8 at the 2 years interval. There were significantly more patients with chemotherapy induced diminished ovarian reserve (chDOR) among the group receiving escalated BEACOPP chemotherapy in comparison with the other types of treatment (58.1% vs. 87.9% resp. 95.5%). CONCLUSION: The rate of chDOR is significantly higher after EB poly-chemotherapy and there is no tendency for improvement in time. The 2 + 2 chemotherapy with GnRH-a required for more advanced HL retained ovarian function significantly better after 2 years. Another important advantage of GnRH-a co-treatment is the excellent control of patient's menstrual cycle.

• MeSH
• dospělí MeSH
• folikuly stimulující hormon krev   MeSH
• Hodgkinova nemoc farmakoterapie   patofyziologie   MeSH
• hormon uvolňující gonadotropiny analogy a deriváty   MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• ovarium účinky léků   fyziologie   MeSH
• prospektivní studie MeSH
• protokoly protinádorové kombinované chemoterapie škodlivé účinky   terapeutické užití   MeSH
• těhotenství MeSH
• zachování plodnosti metody   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• pozorovací studie MeSH
• práce podpořená grantem MeSH

Úvod: Těžká sepse je stále spojena s významnou morbiditou a mortalitou, která se nicméně liší, stejně jako její management, v závislosti na regionu. Jaká je situace v ČR a jaký mají charakter pacienti s těžkou sepsí v současné době, není známo. Cílem projektu je popsat procesy péče, výsledek léčby a charakteristiku pacientů s těžkou sepsí přijímaných na pracoviště intenzivní péče v ČR. Metodika: Jedná se o multicentrický a observační projekt s retrospektivním zařazováním pacientů, kteří splní kritéria těžké sepse před nebo do 24 hod od přijetí na vybrané jednotky intenzivní péče (EPOSS‐ICU). Výsledky: Analyzováno bylo 394 pacientů. Medián věku při přijetí byl 66 (56–76) let, převažovali muži (58,9 %) a medián APACHE II skóre při příjmu byl 25 (19–32). Příjímaní pacienti byli převážně interního charakteru (56,9 %) a nejvíce příjmů bylo sekundárních z jiných ICU (53,6 %). Splnění kritérií těžké sepse bylo nejčastěji v období (? 4 hod) od příjmu na EPOSS‐ICU (77,6 %). Medián celkového příjmu tekutin během prvních 24 hod byl 6 680 (4 840–9 450) ml. Většina nemocných vyžadovala umělou plicní ventilaci (58,4 %). Splnění tzv. resuscitačních balíčků pro těžkou sepsi bylo v našem souboru velmi dobré a bylo spojeno s nižší mortalitou pacientů. Nejčastěji byla délka pobytu na EPOSS‐ICU 7 (3–15) dnů a medián celkové doby hospitalizace v nemocnici byl 13 (8–28) dnů. Celková nemocniční mortalita souboru byla 35,8 %. Závěr: Představujeme projekt, který ve své první fázi získal cenná a mezinárodně srovnatelná data o pacientech s těžkou sepsí přijímaných na zapojená pracoviště intenzivní péče v ČR.

Introduction: Severe sepsis is still associated with significant morbidity and mortality, which is however different, as well as its management, depending on the region. What is the situation in the Czech Republic and what is the character of patients with severe sepsis is currently not known. The aim of the project is to describe the processes of care, outcome and characteristics of patients with severe sepsis admitted to the intensive care department of the Czech Republic. Methods: This is a multicentre and observational project with retrospective enrollment of patients who meet the criteria for severe sepsis before or within 24 hours after admission to selected intensive care units (ICU‐EPOSS). Results: 394 patients were analyzed. Median age at admission was 66 (56–76) years, males predominated (58.9%) and the median APACHE II score on admission was 25 (19–32). Patients were predominantly medical (56.9%) and most were secondary admitted from other ICU (53.6%). Meeting the criteria of severe sepsis was most frequently within the period (? 4 hours) of admission the EPOSS‐ICU (77.6%). Median total fluid intake during the first 24 hours was 6,680 (4,840–9,450) ml. Most patients required mechanical ventilation (58.4%). Compliance with the resuscitation bundle of severe sepsis in our group was very good and was associated with lower mortality of patients. Most frequently, the EPOSS‐ICU length of stay (LOS) was 7 (3–15) days and median hospital LOS was 13 (8–28) days. Hospital mortality in our cohort was 35.8%. Conclusion: Introducing the project, which in its first stage obtained valuable and internationally comparable data about patients with severe sepsis admitted to the involved ICU in the Czech Republic.

• MeSH
• antibakteriální látky terapeutické užití   MeSH
• APACHE MeSH
• délka pobytu statistika a číselné údaje   MeSH
• dodržování směrnic MeSH
• hodnocení výsledků zdravotní péče * statistika a číselné údaje   MeSH
• jednotky intenzivní péče * normy   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mortalita v nemocnicích MeSH
• pilotní projekty MeSH
• retrospektivní studie MeSH
• senioři MeSH
• sepse * epidemiologie   mortalita   terapie   MeSH
• statistika jako téma MeSH
• tekutinová terapie statistika a číselné údaje   MeSH
• umělé dýchání statistika a číselné údaje   MeSH
• vyhodnocení orgánové dysfunkce MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• multicentrická studie MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Česká republika MeSH

• Publikační typ
• abstrakt z konference MeSH